CARLA ODOM: Open Payments
NPI 1043827900 · KOKOMO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$296 in 14 payments from 8 companies in 2025. Trend: 2023 $168 · 2024 $197 · 2025 $296
Food & beverage: $296
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $67 |
| Lilly USA, LLC | 3 | $56 |
| Amgen Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $3 |
Products named: XIFAXAN, Wegovy, MOUNJARO, REPATHA, CAPLYTA, Ozempic, OTEZLA, GVOKE HYPOPEN.
Industry payments across MS — which companies pay providers there.
